Barclays analyst Geoff Meacham maintained a Buy rating on Neurocrine (NBIX) yesterday and set a price target of $95. The company’s shares closed yesterday at $73.83, close to its 52-week low of $64.72.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of 4.8% and a 52.1% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Alexion Pharmaceuticals, and Vertex Pharmaceuticals.
Currently, the analyst consensus on Neurocrine is a Strong Buy with an average price target of $115.15, which is a 56.0% upside from current levels. In a report issued on December 5, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $150 price target.
.
See today’s analyst top recommended stocks >>
Neurocrine’s market cap is currently $6.69B and has a P/E ratio of 1357.17. The company has a Price to Book ratio of 14.96.
Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NBIX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders.
